Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy. - Wikidata - awgldk - TriplyDB

Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy.

Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy.

http://www.wikidata.org/entity/Q37038984

about

Investigations of a rabbit (Oryctolagus cuniculus) model of systemic lupus erythematosus (SLE), BAFF and its receptors.Transplanted human umbilical cord mesenchymal stem cells facilitate lesion repair in B6.Fas mice.Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans.Expression and localization of rabbit B-cell activating factor (BAFF) and its specific receptor BR3 in cells and tissues of the rabbit immune system.Update on emerging drug therapies for systemic lupus erythematosus.Stem cell transplantation: progress in Asia.B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.

P2860

Q33521234-673FBA00-0063-4BC6-8CD7-0D1F0A1A33FD Q35156099-9B6848E0-4AF8-4C27-B70A-A0813A9C000A Q35557372-28CE57C5-6F6A-41EB-8E8F-F5C004B1FEFA Q37246560-ADCA5977-42CF-4582-99CF-F8485DEC9F6F Q37348896-2CDDAED5-00A8-4083-B7D7-B862F1B8DFF7 Q37690745-3A507704-4FB2-4AF6-BED9-766248E13CD5 Q37800307-B9113177-C203-4D79-9893-2A3685C4C62F Q38097129-A8313C9C-8D88-4541-BDA6-83CD944FFECC

P2860

Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy.

http://www.wikidata.org/entity/Q37038984

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Systemic lupus erythematosus: ...... ns for a therapeutic strategy.

@en

Systemic lupus erythematosus: ...... ns for a therapeutic strategy.

@nl

type

label

Systemic lupus erythematosus: ...... ns for a therapeutic strategy.

@en

Systemic lupus erythematosus: ...... ns for a therapeutic strategy.

@nl

prefLabel

Systemic lupus erythematosus: ...... ns for a therapeutic strategy.

@en

Systemic lupus erythematosus: ...... ns for a therapeutic strategy.

@nl

P1433

Q37038984-63FA1C3E-E027-4F6A-A9EC-027E25DC7485

P1476

Q37038984-CD5E39A2-3BA1-45CF-9A22-D7A43896315D

P2093

Q37038984-CB4A364F-F4B1-480A-ABE5-1F3EC70F7A15

Q37038984-F668056D-63B1-4DC0-9201-C0AFF3F698D7

P2860

Q37038984-035B3E92-BF2F-4326-94A8-081795E9A99E

Q37038984-0472120F-53F5-4A46-8E18-43538CC07888

Q37038984-065B680E-28B0-404D-A517-A20B6F64994A

Q37038984-12BD81F2-B653-44E3-90F0-D3B668DED55A

Q37038984-1837A258-E3B6-4478-A855-90A98C2BA72D

Q37038984-1D89C55E-604E-4D6F-B2FF-BDAFE499C6EF

Q37038984-28143D5C-881B-4191-9B75-970101839BF7

Q37038984-2F2354F7-3F28-45AF-B899-8C823FF243DE

Q37038984-3283C63C-E388-479F-A8AA-430CDFE8EBDF

Q37038984-3B01A978-C2C4-446D-AA61-A1E064582542

P304

Q37038984-87F13A8F-F8AD-41FF-906B-3C9CDEDACABF

P31

Q37038984-4EB81B76-C7E6-4935-AC38-428F50DC0A0B

P356

Q37038984-B4FD00E0-FBE4-4C1E-B1F9-9FD716A38E93

P407

Q37038984-8AAD128C-AF32-4200-B60C-1510832A835A

P433

Q37038984-3EC4242E-9DBE-4722-B3FD-39E37F5E5414

P478

Q37038984-C2F5D676-7623-4E90-98C8-850F2CE78A58

P577

Q37038984-AB753AD0-2D70-4A3A-B75F-AF99F59D7102

P698

Q37038984-7B7E9FD4-C5C2-4DC9-9A50-F5F0A2B08929

P921

Q37038984-C0D495B7-19F2-49BF-84ED-F76EDFB8879E

P356

13543784.17.1.31

P1433

Expert Opinion on Investigational Drugs

P1476

Systemic lupus erythematosus: ...... ns for a therapeutic strategy.

@en

P2093

David A Isenberg

http://www.w3.org/2001/XMLSchema#string

Jose Maria Pego-Reigosa

http://www.w3.org/2001/XMLSchema#string

P2860

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF

The 1982 revised criteria for the classification of systemic lupus erythematosus

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Anti-dsDNA antibody up-regulates interleukin 6, but not cyclo-oxygenase, gene expression in glomerular mesangial cells: a marker of immune-mediated renal damage?

Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil.

The central and multiple roles of B cells in lupus pathogenesis.

Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.

P304

31-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.17.1.31

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18095917

http://www.w3.org/2001/XMLSchema#string

P921